Abstract
Tislelizumab - a humanized, monoclonal antibody for programmed cell death protein 1 - has demonstrated significantly improved progression-free survival (PFS) and reduced risk of progression versus standard of care in advanced lung cancer (NCT03432598, NCT03594747). We conducted a Phase 3, multicenter, randomized, open-label study to assess the safety and efficacy of tislelizumab plus chemotherapy in patients with advanced squamous non-small cell lung cancer (NSCLC) (NCT03594747). Here, we report results from patients with stage IIIB disease.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
